High-risk Myelodysplastic Syndromes With Excess Blasts Clinical Trial
— MYRAGEOfficial title:
High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)
Myelodysplastic syndromes (MDS) are the most frequent myeloid neoplasms in Western
Countries.They mainly affect patients aged 65 years or older. This is a very heterogenous
group of diseases, which prognosis is evaluated with International Prognosis Scoring System.
High risk MDS present with high frequency of transformation into acute myeloid leukemia.
Treatment of high risk MDS often is based on hypomethylating agents, such as 5'-azacytidine
(Azacytidine), with a complete response in approximativel 20% of cases..
This treatment is based on 4-week cycles, with daily injection during the first week and rest
during the 3 next weeks of the cycle.
Azacytidine efficacy is commonly evaluated with clinical and biological parameters determined
by the International Working Group 2006. These parameters are usually evaluated after at
least 6 cycles of treatments.
There is a response with Azacytidine treatment in 60% of cases, including 40% of partial
responses and 20% of complete responses. In 40% of patients, there is no response, which
means that the disases is stable or in progression under therapy.
In this regard, early evaluation of treatment response is an issue. We want to improve our
knowledge about early response criteria in Azacytidine-treated high-risk MDS, focusing on SMD
with excess blasts, which represent 30 to 40% of total MDS.
Then, the investigator team want to compare DNA methylation profile at diagnosis and after 3
cycles of Azacytidine treatment.
Main objective :
Identify DNA methylation profiles related to response to Azacytidine therapy, after only 3
cycles of treatment, in high risk MDS with excess blasts.
Secondary objective :
Identify at diagnosis DNA methylation profiles that are predicitive of response to
Azacytidin, in high risk MDS with excess blasts.
| Status | Recruiting |
| Enrollment | 32 |
| Est. completion date | January 1, 2022 |
| Est. primary completion date | January 1, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Pre-inclusion Criteria: - patient benefiting from social welfcare - patient followed at the University Hospital of Nancy - patient aged 18 years or older - patient informed on research organization and having signed an informed pre-inclusion consent - No personal history of myelodysplastic syndrome - clinical exam adapted to research - one or more blood cytopenia Inclusion Criteria: - patient benefiting from social welfcare - patient followed at the University Hospital of Nancy - patient aged 18 years or older - patient informed on research organization and having signed an informed inclusion consent - definitive diagnosis of high risk myelodysplastic syndrome with excess blasts - eligibility to an Azacytidine therapy as first-line treatment Exclusion Criteria: - personal history or current other cancer - immediate acute myeloid leukemia - personal history of demethylation treatment - pregnant or breast feeding women - life-theatening condition - guardianship - imprisoned patients |
| Country | Name | City | State |
|---|---|---|---|
| France | CHRU de Nancy | Nancy | |
| France | BROSEUS | Vandoeuvre les Nancy |
| Lead Sponsor | Collaborator |
|---|---|
| Central Hospital, Nancy, France | Inserm U954 - N-GERE (Nutrition, Genetics and Exposition to Environmental Risk) |
France,
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. doi: — View Citation
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Jun 30;364(26):2496-506. doi: 10.1056/NEJM — View Citation
Chen G, Broséus J, Hergalant S, Donnart A, Chevalier C, Bolaños-Jiménez F, Guéant JL, Houlgatte R. Identification of master genes involved in liver key functions through transcriptomics and epigenomics of methyl donor deficiency in rat: relevance to nonal — View Citation
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Gr — View Citation
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Berna — View Citation
Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE. E — View Citation
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Ma — View Citation
Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM). Impact of TET2 mutations on response rate t — View Citation
Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Micol JB, Selimoglu-Buet D, Masala E, Allione B, Gioia D, Poloni A, Lunghi M, Solary E, Abdel-Wahab O, Santini V, Figueroa ME. Specific molecular signatures predict decitabine response in chronic myelomonocytic — View Citation
Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, Mukherjee S, Kalaycio M, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA. Incorporation of molecular data into the Revised International Prognostic Scoring System in t — View Citation
Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 2015 May 1;2 — View Citation
Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Crit Rev Oncol Hematol. 2013 Nov;88(2):231-45. doi: 10.1016/j.critr — View Citation
Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017 Jan;17(1):5-19. doi: 10.1038/nrc.2016.112. Epub 2016 Nov 11. Review. — View Citation
* Note: There are 13 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Methylation level of the Differentially Methylated Regions (DMR) | 3 months (after 3 cycles of treatment) | ||
| Primary | Overall response by IWG 2006 response criteria (complete remission / partial remission / non response) | At the treatment response assessment (After 6-12 cycles of treatment up to 52 weeks) | ||
| Secondary | Methylation level of the Differentially Methylated Regions (DMR) | At diagnosis | ||
| Secondary | Cytogenetic response by IWG 2006 response criteria (major / minor / no response) | At the treatment response assessment (After 6-12 cycles of treatment up to 52 weeks) | ||
| Secondary | Hematologic improvement by IWG 2006 response criteria (major / minor / no response) | At the treatment response assessment (After 6-12 cycles of treatment up to 52 weeks) | ||
| Secondary | Transfusion independence (yes/no) | At the treatment response assessment (After 6-12 cycles of treatment up to 52 weeks) | ||
| Secondary | General condition improvement (yes/no) | At the treatment response assessment (After 6-12 cycles of treatment up to 52 weeks) |